Lecanemab Injection Market Report 2026

Lecanemab Injection Market Overview

• Lecanemab Injection market size has reached to $2.53 billion in 2025 • Expected to grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 21.2% • Growth Driver: Surge In Prevalence Of Alzheimer’s Disease Fueling The Market Growth Due To Rising Demand For Disease?Modifying Therapies • Market Trend: Transforming Alzheimer’s Care With Disease-Targeting Monoclonal Antibody Therapy, Early Intervention, And Expanded EU Access • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lecanemab Injection Market?

Lecanemab injection is a monoclonal antibody therapy designed to target and remove amyloid-beta plaques in the brain. Its primary purpose is to slow cognitive decline in patients with early-stage Alzheimer’s disease by reducing the buildup of these toxic proteins. It is administered intravenously under medical supervision as part of Alzheimer’s treatment. The main types of lecanemab injection include 200 mg per vial and 500 mg per vial presentations. The 200 mg per vial lecanemab injection refers to a standardized monoclonal antibody dosage formulation designed for precise titration and controlled administration in patients with Alzheimer’s disease, particularly during early and mild stages of treatment initiation. The formulation types intravenous infusion and subcutaneous injection. The patient stages, including early Alzheimer’s disease, mild cognitive impairment, and moderate alzheimer’s disease and the age group as divided 60–70 years, 71–80 years, and 81+ years and the distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Lecanemab Injection Market Growth Forecast?

The lecanemab injection market size is expected to see exponential growth in the next few years. It will grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 21.2%. The growth in the forecast period can be attributed to increasing early-stage diagnosis rates, growing acceptance by specialty physicians, rising global aging population, expansion of reimbursement in European markets and increasing patient adherence due to sc formulation. Major trends in the forecast period include technological advancements in blood-based biomarkers, innovations in subcutaneous injection devices, research and development into pre-clinical treatment, developments in simplified monthly dosing and technological advancements in remote patient monitoring.

What Is The Driver Of The Lecanemab Injection Market?

The increasing prevalence of Alzheimer’s disease is expected to propel the growth of the lecanemab injection market going forward. Alzheimer’s disease prevalence refers to the number of people living with clinically diagnosed Alzheimer’s dementia within a population. The prevalence of Alzheimer’s disease is increasing due to aging population, as older age is the primary risk factor for developing the disease. Lecanemab injection supports Alzheimer’s disease management by targeting and reducing amyloid-beta plaques in the brain, a key factor in disease progression. It improves patient outcomes by slowing cognitive decline and enhancing quality of life for individuals living with Alzheimer’s. For instance, in April 2025, according to the Alzheimer’s Association, a United States based nonprofit health organization, around 7.2 million Americans aged 65 and above are living with Alzheimer’s dementia, with nearly three-quarters (74%) aged 75 or older and by 2030, the entire baby boomer generation (born 1946–1964) will have reached 65 years or older, significantly expanding the population at highest risk for Alzheimer’s dementia. Therefore, the increasing prevalence of Alzheimer’s disease is driving the growth of the Lecanemab injection industry.

Key Players In The Global Lecanemab Injection Market

Major companies operating in the lecanemab injection market are Biogen Inc., Eisai Co. Ltd.

Global Lecanemab Injection Market Trends and Insights

Major companies operating in the lecanemab injection market are focusing on developing advanced therapeutic options, such as humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, to offer treatments that go beyond symptom management to slow progression of cognitive decline. Humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody refers to a laboratory‑engineered antibody whose variable regions from a non‑human source are grafted onto a predominantly human IgG1 backbone to target a specific antigen while reducing immune rejection. For instance, in August 2025, Eisai Co. Ltd., a Japan‑based innovation‑driven healthcare company, launched Leqembi (lecanemab) in the European Union. It is the first therapy approved by the European Commission that targets an underlying cause of Alzheimer's disease. It includes a dual mechanism that targets both amyloid plaques and protofibrils, which can impact downstream tau accumulation, enabling a direct attack on the disease's biology.

What Are Latest Mergers And Acquisitions In The Lecanemab Injection Market?

In November 2024, Eisai Co. Ltd., a Japan‑based innovation‑driven healthcare company, partnered with the National Center of Neurology and Psychiatry (NCNP) to initiate apolipoprotein E (APOE) genetic testing, supporting the use of anti‑amyloid β antibody treatments such as lecanemab injection (LEQEMBI). Through this collaboration, Eisai and NCNP will study the relationship between APOE genotype and the safety and efficacy of lecanemab treatment, utilise APOE genetic data alongside post‑marketing surveillance data, and support regulatory re‑examination efforts by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to optimise patient outcomes. The National Center of Neurology and Psychiatry (NCNP) is a Japan‑based national research institution.

What Defines the Lecanemab Injection Market?

The lecanemab injection market consists of sales of lecanemab monoclonal antibody injection vials, intravenous infusion formulations, prefilled injection formats, companion diagnostic products for amyloid detection, and supportive administration supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lecanemab Injection Market Report 2026?

The lecanemab injection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lecanemab injection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.